

# Cover letter

Matteo Morra

29 January, 2026

**To:**

Editor-in-Chief

*International Journal of Infectious Diseases*

---

Dear Editor,

On behalf of my co-authors, I am pleased to submit our manuscript entitled “**Exploring the evidence for use of cefiderocol as part of combination therapies: a systematic review of in vitro, in vivo, and clinical studies**” for consideration for publication in the *International Journal of Infectious Diseases*.

Cefiderocol has rapidly become a cornerstone in the management of infections caused by carbapenem-resistant Gram-negative bacteria. However, despite its increasing clinical use, there is substantial uncertainty regarding when and how it should be combined with other agents.

To address this critical knowledge gap, we conducted a comprehensive systematic review integrating *in vitro* synergy studies, *in vivo* experimental models, and clinical data, including an exploratory meta-analysis of comparative clinical cohorts. To our knowledge, this is the most extensive synthesis to date evaluating cefiderocol-based combination therapy across translational and clinical domains.

In line with FAIR science principles and to promote transparency and reproducibility, we have created a public GitHub repository containing the datasets and full analytical code used for the meta-analysis, available at: <https://github.com/mat194/Cefiderocol-Meta-analysis>

We believe this manuscript fits well within the scope and readership of the *International Journal of Infectious Diseases*, as it addresses a highly relevant and timely clinical problem in the management of antimicrobial-resistant infections, combining mechanistic insights with real-world clinical evidence.

This manuscript has not been published previously and is not under consideration for publication elsewhere. All authors have approved the submitted versions and declare no conflicts of interest. This work was part of the CLEARER project (Current cLInical

scEnARIos for the use of cefidErocol in multidrug-Resistant infections: a case study-based approach) supported by the Global Antibiotic Research and Development Partnership ([GARDP](#)).

We sincerely thank you for considering our work and would be pleased to respond to any questions or revisions.

For further correspondence, please contact me at: [matteo.morra@univr.it](mailto:matteo.morra@univr.it)

Yours sincerely,

**Matteo Morra, MD, PhD student**

Infectious Diseases Center for trAnsational REsearch ([ID-CARE](#))

Dep. of Diagnostics and Public Health - University of Verona (Italy)